184 related articles for article (PubMed ID: 33132329)
1. Osimertinib for Lung Squamous Cell Carcinoma: A Case Report and Literature Review.
Yoshimatsu Y; Ebi N; Ooi R; Sueyasu T; Nishizawa S; Munechika M; Yoshimine K; Ko Y; Ide H; Tsuruno K; Tobino K
Intern Med; 2021 Apr; 60(7):1067-1071. PubMed ID: 33132329
[TBL] [Abstract][Full Text] [Related]
2. Successful osimertinib rechallenge following subsequent chemotherapy regimen in a patient with metastatic non-small cell lung carcinoma: a case report.
Han ZJ; Luo N; Li L; Liu ZL
Ann Palliat Med; 2021 Jul; 10(7):8413-8419. PubMed ID: 33977727
[TBL] [Abstract][Full Text] [Related]
3. Rapid intracranial response to osimertinib, without radiotherapy, in nonsmall cell lung cancer patients harboring the EGFR T790M mutation: Two Case Reports.
Koba T; Kijima T; Takimoto T; Hirata H; Naito Y; Hamaguchi M; Otsuka T; Kuroyama M; Nagatomo I; Takeda Y; Kida H; Kumanogoh A
Medicine (Baltimore); 2017 Feb; 96(6):e6087. PubMed ID: 28178168
[TBL] [Abstract][Full Text] [Related]
4. FDA Benefit-Risk Assessment of Osimertinib for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor T790M Mutation.
Odogwu L; Mathieu L; Goldberg KB; Blumenthal GM; Larkins E; Fiero MH; Rodriguez L; Bijwaard K; Lee EY; Philip R; Fan I; Donoghue M; Keegan P; McKee A; Pazdur R
Oncologist; 2018 Mar; 23(3):353-359. PubMed ID: 29242281
[TBL] [Abstract][Full Text] [Related]
5. Clearing of circulating tumour DNA predicts clinical response to osimertinib in EGFR mutated lung cancer patients.
Boysen Fynboe Ebert E; McCulloch T; Holmskov Hansen K; Linnet H; Sorensen B; Meldgaard P
Lung Cancer; 2020 May; 143():67-72. PubMed ID: 32213382
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of osimertinib for lung squamous cell carcinoma with de novo EGFR T790M-positive: Case report and literature review.
Maeda C; Shinada K; Murakami S; Saito H
Thorac Cancer; 2023 Oct; 14(28):2886-2889. PubMed ID: 37641467
[TBL] [Abstract][Full Text] [Related]
7. Osimertinib in T790M-positive and -negative patients with EGFR-mutated advanced non-small cell lung cancer (the TREM-study).
Eide IJZ; Helland Å; Ekman S; Mellemgaard A; Hansen KH; Cicenas S; Koivunen J; Grønberg BH; Brustugun OT
Lung Cancer; 2020 May; 143():27-35. PubMed ID: 32200138
[TBL] [Abstract][Full Text] [Related]
8. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Soria JC; Ohe Y; Vansteenkiste J; Reungwetwattana T; Chewaskulyong B; Lee KH; Dechaphunkul A; Imamura F; Nogami N; Kurata T; Okamoto I; Zhou C; Cho BC; Cheng Y; Cho EK; Voon PJ; Planchard D; Su WC; Gray JE; Lee SM; Hodge R; Marotti M; Rukazenkov Y; Ramalingam SS;
N Engl J Med; 2018 Jan; 378(2):113-125. PubMed ID: 29151359
[TBL] [Abstract][Full Text] [Related]
9. Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status.
Nakashima K; Kimura M; Akamatsu H; Daga H; Imai H; Taira T; Ko R; Hisamatsu Y; Nishino K; Sugimoto T; Miyashita Y; Takahashi T;
Jpn J Clin Oncol; 2019 Jul; 49(7):671-675. PubMed ID: 30920616
[TBL] [Abstract][Full Text] [Related]
10. Efficacy of Osimertinib in Lung Squamous Cell Carcinoma Patients with
Rekowska A; Rola P; Wójcik-Superczyńska M; Chmielewska I; Krawczyk P; Milanowski J
Curr Oncol; 2022 May; 29(5):3531-3539. PubMed ID: 35621675
[TBL] [Abstract][Full Text] [Related]
11. Osimertinib for compound EGFR exon 19 deletion/T790M mutated lung squamous cell carcinoma.
Peng M; Wen Q; Wu X; Yu F; Liu W
Thorac Cancer; 2020 Sep; 11(9):2704-2708. PubMed ID: 32667739
[TBL] [Abstract][Full Text] [Related]
12. ERK inhibition effectively overcomes acquired resistance of epidermal growth factor receptor-mutant non-small cell lung cancer cells to osimertinib.
Li Y; Zang H; Qian G; Owonikoko TK; Ramalingam SR; Sun SY
Cancer; 2020 Mar; 126(6):1339-1350. PubMed ID: 31821539
[TBL] [Abstract][Full Text] [Related]
13. Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M-positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study.
Takahama T; Azuma K; Shimokawa M; Takeda M; Ishii H; Kato T; Saito H; Daga H; Tsuboguchi Y; Okamoto I; Otsubo K; Akamatsu H; Teraoka S; Takahashi T; Ono A; Ohira T; Yokoyama T; Sakai K; Yamamoto N; Nishio K; Nakagawa K
Cancer; 2020 Jan; 126(9):1940-1948. PubMed ID: 32022929
[TBL] [Abstract][Full Text] [Related]
14. Real-world data on treatment outcomes in
Dal Maso A; Lorenzi M; Ferro A; Pilotto S; Cecere F; Follador A; Polo V; Del Conte A; Sartori G; Giavarra M; Scattolin D; Indraccolo S; Frega S; De Maglio G; Menis J; Bonanno L; Calabrese F; Guarneri V; Conte P; Pasello G
Future Oncol; 2021 Jul; 17(19):2513-2527. PubMed ID: 33988036
[TBL] [Abstract][Full Text] [Related]
15. Osimertinib, a third-generation tyrosine kinase inhibitor targeting non-small cell lung cancer with EGFR T790M mutations.
McCoach CE; Jimeno A
Drugs Today (Barc); 2016 Oct; 52(10):561-568. PubMed ID: 27910964
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore.
Aziz MIA; Foo WYX; Toh CK; Lim WT; Ng K
J Med Econ; 2020 Nov; 23(11):1330-1339. PubMed ID: 32886557
[TBL] [Abstract][Full Text] [Related]
17. Choroidal metastasis from non-small-cell lung cancer responsive to Osimertinib: a case report : Efficacy of a third-generation epidermal growth factor tyrosine kinase inhibitor.
Mariachiara M; Celeste R; Federico F; Nicole B; Antonio C
Int Ophthalmol; 2018 Dec; 38(6):2669-2675. PubMed ID: 29071523
[TBL] [Abstract][Full Text] [Related]
18. Osimertinib, a third-generation EGFR tyrosine kinase inhibitor: A retrospective multicenter study of its real-world efficacy and safety in advanced/recurrent non-small cell lung carcinoma.
Kishikawa T; Kasai T; Okada M; Nakachi I; Soda S; Arai R; Takigami A; Sata M
Thorac Cancer; 2020 Apr; 11(4):935-942. PubMed ID: 32129931
[TBL] [Abstract][Full Text] [Related]
19. Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation.
Bollinger MK; Agnew AS; Mascara GP
J Oncol Pharm Pract; 2018 Jul; 24(5):379-388. PubMed ID: 28565936
[TBL] [Abstract][Full Text] [Related]
20. Significant Benefits of Osimertinib Against Adenosquamous Carcinoma Harboring Germline T790M Mutation.
Huo R; Li J; Li X; Shi J; Wang K; Jiao J; Shang Y
Oncologist; 2020 Oct; 25(10):826-832. PubMed ID: 32367600
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
